Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) develops and commercializes insulin-delivery systems and related diabetes technology for people with insulin-dependent diabetes. Its durable insulin pumps include the t:slim X2 and Tandem Mobi, which can be used with continuous glucose monitors and the Control-IQ+ automated… From the company’s description.
Over the twelve months to Sep 30, 2026, Tandem Diabetes Care, Inc. reported revenue of $1.08B, up 6.8% from a year earlier, and a net loss of $49.23M. Its operating margin was −2.4%, and operations used $14.61M in cash. In fiscal 2025, it reported revenue of $1.01B, up 7.9% from fiscal 2024, and a net loss of $204.71M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tandem Diabetes Care, Inc. does
In the company’s own words
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) develops and commercializes insulin-delivery systems and related diabetes technology for people with insulin-dependent diabetes. Its durable insulin pumps include the t:slim X2 and Tandem Mobi, which can be used with continuous glucose monitors and the Control-IQ+ automated insulin-delivery algorithm to adjust insulin dosing. The company also sells replacement cartridges and infusion sets, and offers software and data services including Tandem Source, the Tandem Device Updater and Sugarmate. Its customers include people with diabetes, their caregivers and healthcare providers; products are sold through direct operations and independent distributors in more than 25 countries. Tandem serves nearly 500,000 people worldwide. In 2025, its Control-IQ+ technology was indicated in the United States for adults with type 2 diabetes requiring intensive insulin therapy, as well as for people with type 1 diabetes ages two and older. Its pump portfolio also integrates with sensors from Dexcom and Abbott.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- San Diego, CA
- Fiscal year end
- December
- CIK
- 1438133
- SIC
- 3841
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tandem Diabetes Care, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tandem Diabetes Care, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Tandem Diabetes Care, Inc.’s bonds, as funds hold them
Funds report holding 2 issues of Tandem Diabetes Care, Inc.’s debt, $46.25M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.50%, maturing 2029 to 2032.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tandem Diabetes Care, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tandem Diabetes Care, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tandem Diabetes Care, Inc.'s last four quarterly filings that the numbers alone won't show?”